Celgene Earnings Preview: Analysts Expect Higher EPS, Revenue
Celgene (NASDAQ: CELG) announces its next round of earnings this Thursday, October 27, 2011. Here's Benzinga's advanced look at Celgene's third quarter earnings report.
Earnings and Revenue:
Ahead of the company's earnings announcement, analysts are expecting a positive EPS reading of 86 cents/share and revenues of $1.2 billion. Celgene's latest numbers will no doubt be compared with the company's year-ago quarter, when it reported a profit of 65 cents/share on revenues of $908.1 million. We'll have to wait for Thursday to see if Celgene has accomplished the estimated 32.3% rise in EPS and 32.1% increase in revenues on a year-over-year basis.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q2 | Q1 | Q4 | Q3 |
| EPS Estimate | $0.77 | $0.73 | $0.67 | $0.64 |
| EPS Actual | $0.78 | $0.71 | $0.65 | $0.65 |
Stock Performance:
As of October 24, 2011, Celgene's current share price was $67.86. Since January 1st, shares of Celgene have given investors a return of 14.7%.
Average Stock Rating:
The average rating by analysts for Celgene is a Moderate Buy. Over the past three months this rating's strength has declined slightly.
Competitors:
Looking for a sympathy stock to trade or interested in the performance of other companies in the same sector? Take a look at some of Celgene's peers.
- Bristol-Myers Squibb (NYSE: BMY): Hold with a $0.56 recent quarter EPS
- GlaxoSmithKline plc (NYSE: GSK): Hold with a $0.81 recent quarter EPS
- Cell Therapeutics (CTIC): Strong Buy with a -$0.14 recent quarter EPS
The medical-bioengineering company's industry has seen price/earnings growth of 0.3% during the current fiscal year.
Finally, a description of the company's main areas of operation: Celgene is a biopharmaceutical company that develops innovative therapies to treat cancer and immune-inflammatory related diseases.
Take Action:
There is your peek into Celgene's upcoming earnings numbers, including some competitors to watch around the time of the announcement. Check back in with us after the announcement for a full recap. In the meantime, here are some links to explore today.
- To see up-to-date news on Celgene, click here
- To see other trading ideas, click here
- To see other company earnings recaps, click here
